BPC-157, KPV and the 2026 FDA compounding decision

TL;DR

• Six of seven recommended - on 23–24 July 2026 the PCAC backed BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, voting against only Emideltide (DSIP).
• The vote was about lawful manufacture, not efficacy - it asked whether pharmacies may compound these substances, not whether they work.
• Nonbinding - the FDA alone decides the 503A bulks list, and the remaining sequence is docket review, proposed rule, public comment, final rule; only the first step has happened.
• Removal from Category 2 is not authorisation - the April 2026 removal did not place any of these peptides on an approved list.
• Recommended is not available - on 14 October 2026 HHS/FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for review; it has not been issued, its text is not public, and which peptides it covers is unknown.
• Neither compound has completed human trials - BPC-157 rests on animal and cell models, with pro-angiogenic cancer-relevant cautions and a WADA flag; KPV has zero human trials for any indication. Efficacy in people is unestablished, not disproven, because those trials have not been run.
• Sourcing is the real hazard - most product in circulation is "research-use-only" grey market of unverified identity, purity and contaminants, which is exactly the gap a properly regulated pathway would be designed to close.

Educational content, not medical advice. No doses or protocols appear. Regulatory status is evolving; this reflects the position as of 19 October 2026 and should be updated as the FDA acts.

Updated October 2026: adds the 14 October 2026 submission of an FDA/HHS interim peptide compounding policy to OMB review (not issued, text not public, coverage unknown) and states plainly that a PCAC recommendation is not availability; BPC-157 and KPV remain off the 503A Bulks List as of 19 October 2026.

Updated September 2026: confirms nothing has advanced since the vote: as of 1 September 2026 no proposed rule has been published, BPC-157 and KPV are not on the final 503A Bulks List, and no interim enforcement policy has been announced.

Updated August 2026: records the outcome of the 23–24 July 2026 advisory vote - BPC-157 and KPV both recommended - and states plainly that the vote is nonbinding and legal status is unchanged.

---

If you follow peptides, you've seen the confusion: BPC-157 and KPV are everywhere online, yet their legal status keeps shifting. A key moment came on 23–24 July 2026, when the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed whether these peptides belong on the list of substances that compounding pharmacies may lawfully use. It was an important step - and it was widely misunderstood. That review was about whether pharmacies may lawfully make these peptides, not about whether they work. On the second question, the answer hasn't changed: there are no completed human trials for either. Here's the honest picture.

What was decided - and what wasn't

The regulatory path has been winding:

• September 2023 - the FDA placed BPC-157, KPV and a group of other peptides (including TB-500 and MOTS-c) into 503A "Category 2" - substances with significant safety questions, effectively restricting compounding.
• April 2026 - the FDA removed these peptides from Category 2. This sounds like good news, but it's widely misread: removal from Category 2 does not authorize compounding. It doesn't place them on the approved list.
• 23–24 July 2026 - the PCAC voted on whether these peptides should be added to the 503A Bulk Drug Substances List - the list that would actually permit legal compounding. Both BPC-157 and KPV were recommended, alongside TB-500, MOTS-c, Epitalon and Semax. The committee voted against recommending one substance, Emideltide (also referred to as DSIP). Six in, one out. The full account is in the FDA vote recap.

The favourable vote did not flip a switch. The PCAC is an advisory committee; its votes are nonbinding and did not make any of these substances lawful for compounding under Section 503A. The FDA alone decides what goes on the bulks list, and the sequence still to run is: advisory vote → FDA docket review → proposed rule → public comment period → final rule. Only the first step has happened. The FDA has finalised nothing, and the legal status of BPC-157 and KPV is unchanged today - exactly as it was the week before the meeting. Estimates for that rulemaking run to many months; realistically nothing is settled before late 2027, and the agency may decline at any point.

October 2026: an interim policy at the White House, not yet in force

On 14 October 2026 HHS and the FDA submitted a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Information and Regulatory Affairs at the White House Office of Management and Budget. As of 19 October 2026 it is pending review. It has not been issued, and its text is not public, so which peptides, routes of administration and conditions it covers is unknown. Press reports have said the plan would let pharmacies temporarily compound some popular peptides including BPC-157; whether KPV is included has not been confirmed.

Law firms reading the filing expect a form of enforcement discretion: the FDA signalling it would not plan to act against 503A pharmacies compounding certain peptides for individual patients, subject to conditions. If that is what it turns out to be, it would not approve any product, would not add anything to the 503A Bulks List, and could be narrowed or withdrawn without notice-and-comment. Legal commentary also expects it would not cover research-use-only products, dietary supplements or 503B outsourcing facilities, and would not bind state pharmacy boards. FDA is also funded only through a temporary spending measure to 11 December 2026, which is a timing risk in itself.

Recommended is not available. A favourable committee vote does not make BPC-157 or KPV lawful to compound, and an interim policy that has not been published does not either. Until a final text appears, nobody can say which of the six recommended peptides it reaches, or on what terms.

What it does not change

This is the part to hold onto. The compounding question is separate from the evidence question, and on evidence:

• BPC-157 - a synthetic peptide studied almost entirely in animals and cell models; there are no adequate human trials establishing efficacy or safety, and it carries theoretical cancer-relevant cautions from its pro-angiogenic activity, plus a WADA anti-doping flag.
• KPV - an anti-inflammatory α-MSH fragment with genuinely interesting preclinical data (especially in the gut), but again zero human trials for any indication (full picture here).

A place on a compounding list would make legal, quality-controlled production possible; it would not mean the FDA had reviewed these peptides for safety and effectiveness the way it reviews an approved drug. That distinction matters - and it is precisely the distinction a committee recommendation cannot bridge. It's also why the vote drew serious criticism as well as celebration: commentators have argued that widening compounded-peptide access without stronger clinical evidence risks lending medical legitimacy to therapies whose risks remain poorly characterised. That case is set out alongside the counter-case in the FDA vote recap.

Why the sourcing problem is the real story

Because regulated access has been restricted - and remains so - most BPC-157 and KPV in circulation comes from the "research-use-only" grey market: product of unverified identity, purity and contaminants. That's the actual hazard for most people, and it is unaffected by how the July vote went. If these peptides do eventually move toward legal compounding through rulemaking, the upside is precisely that it would pull them out of that grey market into pharmacies with quality standards. Until then, the unverified-source risk stands.

The bottom line - and where to start

The July 2026 PCAC vote is a real milestone in a long regulatory story: it could, in time, move BPC-157, KPV and others toward legal compounding - or not, because the FDA is not bound by it - but either way it doesn't resolve the deeper issue, which is that these peptides remain unproven in humans, and most of what's sold is unverified grey-market product. The sensible stance is the same before and after the vote: if a peptide is worth considering, it's worth doing with verified product under a clinician who knows the evidence - and its limits.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore BPC-157.

Frequently asked questions

Is BPC-157 legal in 2026? Its status is in flux, but it did not change with the vote. It was restricted (Category 2) in 2023, removed from that category in April 2026 (which does not authorize compounding), and recommended by an FDA advisory committee in July 2026 for possible inclusion on the 503A bulks list. That recommendation is nonbinding: the FDA has finalised nothing. It is not an FDA-approved drug, and most available product is unregulated grey-market.

Did the July 2026 vote make KPV legal to compound? No. KPV was among the six substances the committee recommended, but a favourable advisory vote is not an approval and changes nothing legally. The FDA would still have to accept the recommendation and complete notice-and-comment rulemaking - proposed rule, public comment, final rule - before lawful compounding could resume.

Does the FDA decision mean these peptides work? No. The compounding question is about whether pharmacies may lawfully make them, not whether they're proven. Both BPC-157 and KPV lack completed human trials for any indication.

Related reading

• After the FDA vote: what actually changed · BPC-157: the honest guide · KPV: the honest guide · The honest peptide side-effects guide · Is compounded semaglutide legal?
• Part of The Complete Guide to Peptides

---

Educational content, not medical advice. Regulatory status is evolving and US-specific; PCAC recommendations are nonbinding and do not change legal access. This reflects the position as of 19 October 2026 and should be updated as the FDA acts. Claims for the Malaysian market are subject to MAB requirements.

References

• FDA 503A bulk drug substances process: BPC-157, KPV and others (TB-500, MOTS-c) placed in Category 2 (Sept 2023), removed from Category 2 (Apr 2026 - removal does not authorize compounding). · FDA Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026, on peptide bulk drug substances for the 503A Bulks List (FDA advisory committee calendar). Outcome: the committee voted in favour of BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, and against recommending Emideltide (also referred to as DSIP). · The votes are nonbinding and did not make any of these substances lawful for compounding under Section 503A; FDA retains sole authority over the 503A Bulks List, and the remaining sequence is FDA docket review → proposed rule → public comment → final rule. Nothing has been finalised as of 20 August 2026. · Regulatory analysis: Buchanan Ingersoll & Rooney, "FDA PCAC Recommends Six Peptides for the 503A Bulks List" and "FDA Voted Yes on Six Peptides - Now What"; counter-argument in Health Affairs Forefront (2026), "FDA Advisory Committee's Vote May Open Drug Compounding Back Door For Unapproved Peptides." · BPC-157 and KPV: preclinical evidence only, no completed human trials for any indication.
• Interim policy: HHS/FDA submitted "Interim Access Policy for Compounding Using Certain Peptides" to OIRA/OMB for review on 14 October 2026; pending review, not issued, text not public as of 19 October 2026; likely mechanism enforcement discretion (law-firm analysis, not an FDA statement). Sources: Buchanan Ingersoll & Rooney (16 October 2026) https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know · Holland & Knight, "Peptides at a Crossroads" (October 2026) https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know · Becker's Hospital Review (15 October 2026) https://www.beckershospitalreview.com/glp-1s/hhs-sends-peptide-compounding-plan-to-white-house-5-things-to-know/